This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a
novel treatment target for mood disorders through the administration of the KCNQ-selective
channel opener XEN1101 (Xenon Pharmaceuticals).
Phase:
Phase 2
Details
Lead Sponsor:
James Murrough
Collaborators:
Baylor College of Medicine National Institute of Mental Health (NIMH)